Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational I...( - PAH Pathways(TM) Program offers Pa...)

- PAH Pathways(TM) Program offers Patient Support and Financial Assistance

-

SOUTH SAN FRANCISCO, Calif., Dec. 18 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc. today announced results of a recent Harris Interactive(R) survey, showing that an overwhelming majority of Tracleer patients enrolled in Sure Steps find the patient support program valuable, and feel that their knowledge of pulmonary arterial hypertension (PAH) and Tracleer have improved due to the program. The Sure Steps program, part of Actelion's PAH Pathways(TM) service and support program, is a support and education program available to all PAH patients on Actelion's PAH products, Tracleer and Ventavis(R) (iloprost) Inhalation Solution.
Key findings from the survey of patients enrolled in Sure Steps show that:

-- Nine in ten (89 percent) enrolled patients are satisfied with the

program;

-- Almost all (97 percent) would recommend the program to other PAH

patients on Tracleer;

-- Six out of seven (85 percent) enrolled patients are more comfortable

discussing their PAH therapy with their physicians because of the

program; and

-- 92 percent feel better informed about Tracleer as a result of

information provided in the program.

The survey was conducted by Harris Interactive on behalf of Actelion between August 7 and August 21, 2007. It included more than 600 patients currently enrolled in Sure Steps, 256 of whom who had been on Tracleer for less than one year, and 354 patients who had been on Tracleer for more than a year. All patients were 18 year of age or older, diagnosed with PAH, currently taking Tracleer, and had been enrolled in the Sure Steps program for at least two months.

"When patients are first diagnosed with PAH and begin treatment, they are often overwhelmed by their diagnosis and have many questions about treatment," said Craig Hopkinson, MD, Vice
'/>"/>